Close this search box.

Beyond Study Design and Primary Outcomes: Lessons Learned from a Deprescribing Trial to Increase Cognitive Reserve

Presenter: Dr. Daniela Moga is an Associate Professor and Larry H. Spears Endowed Chair in Pharmacogenetics in the College of Pharmacy at University of Kentucky.

April 12, 2022 | 2PM ET / 11AM PT

The course of Alzheimer’s disease (AD) includes a 10–20-year preclinical period with progressive accumulation of amyloid β plaques and neurofibrillary tangles in the absence of symptomatic cognitive or functional decline. The duration of this preclinical stage in part depends on the rate of pathologic progression, which is offset by compensatory mechanisms, referred to as cognitive reserve. Comorbid medical conditions, psychosocial stressors, and inappropriate medication use may lower cognitive reserve, hastening the onset of symptomatic AD.

INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer’s Symptomatic Expression: The INCREASE study” was designed to test the efficacy of a deprescribing intervention to reduce inappropriate medication use and bolster cognitive reserve to ultimately delay symptomatic AD. This session will describe issues pertaining to the design and conduct of the INCREASE study; the presenter will discuss challenges and share lessons learned during the study.


Contact Us

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.